Advertisement

Massachusetts medical device maker Ocular Therapeutics posts positive findings for a Phase II clinical trial of its absorbable intracanalicular plug for treatment of post-operative inflammation and pain.

Study: Ocular Therapeutix releases Phase II results for sutained-release eye implant

Ocular Therapeutix, the latest endeavor of serial entrepreneur Amar Sawhney, released positive findings from a Phase II study of its absorbable intracanalicular plug, designed to provide long-term drug therapy following eye surgery.

Ocular Therapeutix enrolled 60 cataract surgery patients in a placebo-controlled, randomized clinical trial designed to evaluate sustained-release dexamethasone in treatment of post-operative inflammation and pain.

Advertisement
Advertisement